Merck & Co., Inc. $MRK Shares Sold by M&T Bank Corp

Key Points

• M&T Bank Corp trimmed its Merck stake by 1.5%, selling 22,631 shares and now holding 1,476,206 shares worth about $155.4 million (≈0.06% of the company), while institutional investors own roughly 76% of MRK.
• Q1 results beat expectations with revenue of $16.29 billion and adjusted EPS above forecasts, Merck set FY‑2026 guidance of $5.04–$5.16 EPS, but a Cidara‑related acquisition charge produced a GAAP loss that clouds headline profitability.
• Insider selling was notable: CEO Robert Davis and CMO Chirfi Guindo sold large blocks (47,434 and 20,000 shares respectively), and insiders dumped 320,176 shares worth about $38.3 million over the last quarter.

M&T Bank Corp cut its holdings in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.5% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 1,476,206 shares of the company's stock after selling 22,631 shares during the period. M&T Bank Corp owned 0.06% of Merck & Co., Inc. worth $155,386,000 at the end of the most recent reporting period.

Several other institutional investors also recently made changes to their positions in MRK. Barnes Dennig Private Wealth Management LLC grew its stake in shares of Merck & Co., Inc. by 302.3% during the 3rd quarter. Barnes Dennig Private Wealth Management LLC now owns 354 shares of the company's stock valued at $30,000 after buying an additional 266 shares during the period. United Financial Planning Group LLC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at $31,000. Wealth Watch Advisors INC purchased a new stake in shares of Merck & Co., Inc. during the 3rd quarter valued at $34,000. Dunhill Financial LLC grew its stake in shares of Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company's stock valued at $35,000 after buying an additional 190 shares during the period. Finally, Silicon Valley Capital Partners grew its stake in shares of Merck & Co., Inc. by 160.5% during the 3rd quarter. Silicon Valley Capital Partners now owns 422 shares of the company's stock valued at $35,000 after buying an additional 260 shares during the period. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $112.30 on Monday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.54 and a quick ratio of 1.30. The firm has a 50-day moving average of $117.69 and a two-hundred day moving average of $107.70. The stock has a market cap of $277.36 billion, a P/E ratio of 31.63, a PEG ratio of 2.27 and a beta of 0.18. Merck & Co., Inc. has a 1-year low of $73.31 and a 1-year high of $125.14.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts' consensus estimates of ($1.47) by $0.19. The company had revenue of $16.29 billion during the quarter, compared to analysts' expectations of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 26.84%. The firm's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the prior year, the company posted $2.22 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts expect that Merck & Co., Inc. will post 4.9 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Merck & Co., Inc. news, CMO Chirfi Guindo sold 20,000 shares of the company's stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $121.88, for a total value of $2,437,600.00. Following the completion of the transaction, the chief marketing officer directly owned 80,615 shares of the company's stock, valued at $9,825,356.20. This represents a 19.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Robert M. Davis sold 47,434 shares of the company's stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $118.04, for a total transaction of $5,599,109.36. Following the completion of the transaction, the chief executive officer directly owned 443,602 shares of the company's stock, valued at approximately $52,362,780.08. The trade was a 9.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 320,176 shares of company stock worth $38,281,735 over the last quarter. Company insiders own 0.17% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Q1 results beat expectations — Merck posted revenue and adjusted EPS above Street forecasts with Keytruda and Winrevair driving growth; the beats and upbeat commentary lifted investor sentiment. Merck tops Q1 estimates
• Positive Sentiment: Regulatory approvals & pipeline progress expand addressable markets — Merck won FDA approval for a new 2‑drug HIV regimen (IDVYNSO) and EC approval for ENFLONSIA for RSV prevention; the company also dosed the first patient in Phase 3 enpatoran lupus trials, adding long‑term growth optionality. Merck expands beyond oncology
• Neutral Sentiment: Analyst action mixed — Wells Fargo trimmed its price target to $145 but kept an Overweight rating, signaling continued confidence despite a modestly lower PT. Wells Fargo lowers PT
• Neutral Sentiment: FY‑2026 guidance and outlook — Merck provided EPS guidance of $5.04–$5.16 and a narrowed sales view ($65.8B–$67.0B). Guidance is close to consensus but tighter ranges mean less revenue upside visibility near term. Merck Q1 financial results
• Neutral Sentiment: Sector context — Biotech peers are mixed (Moderna saw vaccine revenue rebound but its stock fell; Organon missed), so some moves reflect broader healthcare rotation rather than Merck‑specific news. Moderna Covid vaccine drives growth
• Negative Sentiment: Acquisition-related charge produced a GAAP loss — A Cidara-related charge drove a quarterly GAAP loss, which clouds headline profitability despite the operational beat. Merck posts quarterly loss due to Cidara charge
• Negative Sentiment: Longer-term growth risks flagged — Coverage noted potential future pressure from lost sales on some products (e.g., competitive threats to Keytruda, HPV and diabetes medicines) and Merck said it is working on mitigations. That risk keeps some investors cautious. Merck stock falls after earnings

Wall Street Analyst Weigh In

MRK has been the subject of several research reports. Barclays initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They set an "overweight" rating and a $140.00 price objective for the company. Citigroup upped their price target on shares of Merck & Co., Inc. from $120.00 to $125.00 and gave the stock a "neutral" rating in a research report on Friday, March 20th. Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research report on Saturday, March 28th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 price target on shares of Merck & Co., Inc. in a research report on Monday, March 30th. Finally, Cantor Fitzgerald upped their price target on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of "Moderate Buy" and a consensus price target of $128.18.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.